Regeneron Faces Class Action Over Alleged Clinical Trial Misstatements

The class action, filed in the U.S. District Court for the Southern District of New York under the caption Cheathem v. Regeneron Pharm., Inc., claims executives violated federal securities laws by painting an overly optimistic picture of the trial. While Regeneron touted high hopes for the treatment’s ability to differentiate itself from current standards, the complaint alleges the company failed to disclose that the trial was not meeting key statistical benchmarks.

The stock volatility began on April 29, 2026, when Regeneron announced it would expand study parameters to include all patients with at least six months of follow-up. That update triggered a 6.2% drop in the company's share price. The decline deepened on May 15, 2026, when the firm confirmed the trial had failed to reach statistical significance for its primary endpoint, causing an additional 9.8% slide. Investors seeking to serve as lead plaintiff in the litigation have until September 14, 2026, to contact the court.

Legal firm Bleichmar Fonti & Auld LLP is spearheading the action, representing shareholders who purchased stock during the period the company allegedly misrepresented the trial’s progress. The case focuses on potential violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.